<SEC-DOCUMENT>0001415889-25-021797.txt : 20250814
<SEC-HEADER>0001415889-25-021797.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814134427
ACCESSION NUMBER:		0001415889-25-021797
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aura Biosciences, Inc.
		CENTRAL INDEX KEY:			0001501796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				320271970
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92997
		FILM NUMBER:		251217153

	BUSINESS ADDRESS:	
		STREET 1:		80 GUEST STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02135
		BUSINESS PHONE:		(617)500-8864

	MAIL ADDRESS:	
		STREET 1:		80 GUEST STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02135

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Frazier Life Sciences Public Fund, L.P.
		CENTRAL INDEX KEY:			0001863769
		ORGANIZATION NAME:           	
		EIN:				862999645
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		1001 PAGE MILL ROAD
		STREET 2:		BUILDING 4, SUITE B
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		650-325-5156

	MAIL ADDRESS:	
		STREET 1:		1001 PAGE MILL ROAD
		STREET 2:		BUILDING 4, SUITE B
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
		<previousAccessionNumber>0001415889-25-014432</previousAccessionNumber>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001863769</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>1</amendmentNo>
	      <securitiesClassTitle>Common Stock, $0.00001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>06/30/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001501796</issuerCik>        <issuerName>Aura Biosciences, Inc.</issuerName>        <issuerCusip>05153U107</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>80 Guest Street</com:street1>
                    <com:city>Boston</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02135</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>

	        <designateRulesPursuantThisScheduleFiled>
	   				        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
		      </designateRulesPursuantThisScheduleFiled>

    </coverPageHeader>

	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences Public Fund, L.P. </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>3113550.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>3113550.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3113550.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>5.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP, L.P. </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>3113550.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>3113550.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3113550.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>5.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP, L.L.C. </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>3113550.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>3113550.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3113550.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>5.0</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences Public Overage Fund, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>918510.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>918510.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>918510.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.5</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP Overage, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>918510.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>918510.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>918510.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.5</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP Overage, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>918510.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>918510.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>918510.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.5</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences X, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>128520.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>128520.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>128520.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.2</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS X, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>128520.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>128520.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>128520.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.2</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS X, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>128520.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>128520.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>128520.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.2</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences XI, L.P.  </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>342210.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>342210.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>342210.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.6</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XI, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>342210.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>342210.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>342210.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.6</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XI, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>342210.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>342210.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>342210.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.6</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences XII, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>597210.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>597210.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>597210.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XII, L.P.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>597210.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>597210.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>597210.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XII, L.L.C.</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>597210.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>597210.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>597210.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.0</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held by the Reporting Person and do not include any warrants held by the Reporting Person. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>James N. Topper</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>128520.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>128520.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>128520.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.2</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Patrick J. Heron</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>128520.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>128520.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>128520.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.2</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. and do not include any warrants held directly by Frazier Life Sciences X, L.P. See item 4(a) to this Statement.

The percentage listed in row 11 is calculated based the sum of (i) 50,268,758 shares of the Issuer's Common Stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, and (ii) 11,735,565 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Prospectus Supplement filed with the SEC pursuant to Rule 424(b)(5) on May 16, 2025.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Albert Cha </reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>0.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>0.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>0.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>James Brush</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>0.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>0.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>0.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Daniel Estes</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>0.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>0.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>0.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>

    <items>
      <item1>
        <issuerName>Aura Biosciences, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>80 Guest Street, Boston, MA, 02135.</issuerPrincipalExecutiveOfficeAddress>
      </item1>

      <item2>
        <filingPersonName>The entities and persons filing this statement (collectively, the "Reporting Persons") are:

Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P. FHMLSP, L.L.C.
Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF")
FHMLSP Overage, L.P.
FHMLSP Overage, L.L.C.
Frazier Life Sciences X, L.P. ("FLS X")
FHMLS X, L.P.
FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
Frazier Life Sciences XII, L.P. ("FLS XII")
FHMLS XII, L.P.
FHMLS XII, L.L.C.
James N. Topper ("Topper")
Patrick J. Heron ("Heron")
Albert Cha ("Cha")
James Brush ("Brush")
Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members")</filingPersonName>        <principalBusinessOfficeOrResidenceAddress>The address of the principal place of business for each of the Reporting Persons is:

c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite B
Palo Alto, CA 94304
</principalBusinessOfficeOrResidenceAddress>        <citizenship>The information contained in row 4 of each Reporting Person's cover page to this Statement is incorporated by reference.</citizenship>      </item2>

        <item3>
		        <notApplicableFlag>Y</notApplicableFlag>

      </item3>



    <item4>
    <amountBeneficiallyOwned>The information contained in row 9 of each Reporting Person's cover page to this Statement (including the footnotes thereto) is incorporated by reference.

FLSPF directly holds 3,113,550 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.

FLSPOF directly holds 918,510 shares of Common Stock. FHMLSP Overage, L.P. is the general partner of FLSPOF and the general partner of FHMLSP Overage, L.P. is FHMLSP Overage, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPOF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.

FLS X directly holds 128,520 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X.

FLS XI directly holds 342,210 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.

FLS XII directly holds 597,210 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.

The above referenced beneficial ownership and amounts reflected on the cover pages hereto do not include certain prefunded warrants to acquire shares of Common Stock (the "Warrants"), the exercise of which is subject to certain beneficial ownership limitations. In this regard, (i) FLSPF holds Warrants to purchase 778,388 shares of Common Stock, (Ii) FLSPOF holds Warrants to purchase 229,628 shares of Common Stock, (iii) FLS X holds Warrants to purchase 32,130 shares of Common Stock, (iv) FLS XI holds Warrants to purchase 85,552 shares of Common Stock and (v) FLS XII holds Warrants to purchase 149,302 shares of Common Stock, each of which cannot be exercised, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder of such Warrant (together with its affiliates or any other persons acting as a group together with such holder) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Statement or a member of a "group" with any other person.</amountBeneficiallyOwned>    <classPercent>The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

</classPercent>
      <numberOfSharesPersonHas>
        <solePowerOrDirectToVote>The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

</solePowerOrDirectToVote>
        <sharedPowerOrDirectToVote>The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</sharedPowerOrDirectToVote>
        <solePowerOrDirectToDispose>The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

</solePowerOrDirectToDispose>
        <sharedPowerOrDirectToDispose>The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

</sharedPowerOrDirectToDispose>
      </numberOfSharesPersonHas>
    </item4>


        <item5>
	          <notApplicableFlag>Y</notApplicableFlag>


    </item5>


        <item6>
	  	  <notApplicableFlag>Y</notApplicableFlag>
		        </item6>


        <item7>
	  	  <notApplicableFlag>Y</notApplicableFlag>


    </item7>


          <item8>
                <notApplicableFlag>Y</notApplicableFlag>

              </item8>


            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
                      </item9>


      <item10>
                <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>

      </item10>
    </items>

		<exhibitInfo>Exhibit 99.1 Joint Filing Agreement, dated as of May 23, 2025, incorporated by reference into this Statement.</exhibitInfo>

	    <signatureInformation>
      <reportingPersonName>Frazier Life Sciences Public Fund, L.P. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP, L.P. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP, L.L.C. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C. </title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences Public Overage Fund, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP Overage, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP Overage, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences X, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS X, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS X, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C. </title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences XI, L.P.  </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XI, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XI, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C. </title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences XII, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Gordon Empey</signature>
        <title>By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XII, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Gordon Empey</signature>
        <title>By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XII, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Gordon Empey</signature>
        <title>By Gordon Empey, General Counsel of FHMLS XII, L.L.C.</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>James N. Topper</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Patrick J. Heron</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Albert Cha </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>James Brush</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Daniel Estes</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022</title>
        <date>08/14/2025</date>
      </signatureDetails>

    </signatureInformation>



  </formData>

    </edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
